MAC-321

DRUG2 trials

Sponsors

Wyeth is now a wholly owned subsidiary of Pfizer

Conditions

Carcinoma, Non-Small-Cell LungColonic NeoplasmsColorectal NeoplasmsLung NeoplasmsRectal Neoplasms

Phase 2

Study Evaluating MAC-321 in Non-small Cell Lung Cancer Refractory to Platinum-based Therapy

CompletedNCT00063219

Wyeth is now a wholly owned subsidiary of PfizerCarcinoma, Non-Small-Cell Lung, Lung Neoplasms

End: 2005-02-28Updated: 2009-08-21

Study Evaluating MAC-321 in Colorectal Cancer

CompletedNCT00063427

Wyeth is now a wholly owned subsidiary of PfizerColonic Neoplasms, Colorectal Neoplasms, Rectal Neoplasms

End: 2004-02-29Updated: 2009-08-21